Certara is a healthcare software business that provides biosimulation tools to help drug companies predict how new medicines will behave in the human body before they enter clinical trials. The company generated $392 million in revenue in 2024 and serves all of the top 20 pharmaceutical companies in the world. While its service unit has faced headwinds from tighter biotech spending, its high-margin software business is growing and now accounts for roughly 40% of total revenue.
The investment thesis on Certara is that biosimulation is becoming a mandatory part of drug development because it saves companies hundreds of millions of dollars in failed trial costs. Certara’s real advantage is its deep integration into the regulatory process: the FDA and other global regulators use the same Certara software to review drug submissions that the pharma companies use to prepare them. This creates a powerful lock-in where switching to a competitor would risk delaying a multi-billion dollar drug launch.
We think the stock is significantly mispriced because the market is focused on short-term weakness in the service unit while ignoring the compounding value of the software platform. If the software side keeps growing at double digits, Certara should eventually be valued like a high-margin software company rather than a low-margin consultant.
Certara's stock has crashed since it went public and remains down significantly from its peak. The company helps drug makers test medicine on computers to save money, but it has struggled as those clients tightened their budgets. While the business is now trying to cut costs and use more artificial intelligence, investors are currently suing the company over its performance.
What does it do?
Certara is a growth business that earns money by selling specialized biosimulation software and high-end scientific consulting to pharmaceutical companies. The core product is software that uses mathematical models to predict how a drug will interact with the body, which allows companies to run thousands of virtual trials before testing on a single human. Customers pay for annual software subscriptions or hire Certara’s expert scientists for project-based consulting to help design trials and navigate the complex regulatory approval process.
Where does revenue come from?
The majority of revenue still comes from expert services, but the faster-growing software segment is the primary value driver. The business is split between software subscriptions, which provide recurring high-margin revenue, and technology-driven services, which include pharmacometrics and regulatory science consulting. Geographically, about half of the revenue is generated in North America, with the remainder coming from international pharmaceutical hubs in Europe and Asia.
Revenue by Geography
Who are its customers?
Certara serves over 2,400 customers globally, including all of the top 20 biopharmaceutical companies by research and development spend. The company is deeply embedded in the industry: more than 90% of all novel drugs approved by the FDA over the past several years were supported by Certara software or services. In addition to commercial biopharma companies, Certara provides its software to 17 global regulatory agencies, including the FDA in the United States and the EMA in Europe, who use it to verify the data submitted by drug developers.
What gives it staying power?
Certara’s staying power comes from high switching costs and a regulatory moat that is nearly impossible for new rivals to duplicate. Because global regulators use Certara’s software to review drug applications, pharmaceutical companies are effectively forced to use the same tools to ensure their data matches what the regulators see.
Where is it headed?
Certara is pushing to become a software-first company by expanding its platform to cover more of the drug development lifecycle. Management is investing heavily in new areas like Quantitative Systems Pharmacology and Clinical Outcomes Databases to provide a complete "end-to-end" digital laboratory. If successful, this moves the company away from one-off consulting projects toward a more predictable and profitable subscription model.
Revenue is growing steadily but reflects a Tale of Two Cities within the business. Total revenue reached $392 million in 2024, but this masks 17% growth in the software unit being dragged down by a shrinking regulatory services business. This mix shift is positive for long-term investors because every dollar of software revenue is more profitable than a dollar of service revenue.
Cash generation is a core strength, with the business producing reliable free cash flow regardless of reported net income. Certara generated $83 million in free cash flow in 2024, proving that the business can fund its own growth without needing to tap the debt markets. The gap between cash flow and net income is largely due to non-cash accounting charges like the amortization of acquired technology.
The balance sheet is manageable with a healthy cash position and modest debt levels. The company carries roughly $290 million in debt against a cash pile of nearly $200 million, leaving it with low net leverage. This financial flexibility allows Certara to acquire smaller software competitors like Chemaxon to expand its product portfolio without straining its finances.
Certara is a financially resilient business whose underlying profitability is improving as software becomes a larger part of the total mix.
The software segment is accelerating, with bookings growing 17% in the latest quarter as drug companies prioritize digital tools. This growth is expanding gross margins to 58%, as software scales much more efficiently than the labor-heavy services business.
Service bookings fell 9% year-over-year as large pharmaceutical companies pulled back on regulatory consulting projects. If this decline continues or spreads to the core biosimulation services, it could neutralize the gains being made on the software side of the house.
The biosimulation and drug development software market is currently worth roughly $3 billion and is growing at more than 10% annually as drugmakers look to cut costs. Pricing power is structural because the cost of the software is tiny compared to the $2 billion cost of a failed drug trial. Certara is the clear leader in this niche, and as trials become more data-driven, the total market is on track to exceed $5 billion by 2028. The industry is shifting from manual lab work to "in-silico" or virtual testing, which Certara dominates.
The competitive dynamic is fairly rational because the specialized scientific expertise required to build these models acts as a high barrier to entry. Competition is less about price and more about the scientific accuracy of the models and their acceptance by global regulators. High barriers to entry protect the industry from new tech startups that lack decades of clinical data.
Certara’s main rival, Simulations Plus, is smaller and often targets different stages of the drug cycle, while Schrödinger focuses on discovery rather than simulation. The largest threats are actually from giant clinical research organizations like ICON that try to bundle their services. The most dangerous threat is a shift toward large service firms that offer their own proprietary software as part of a broader consulting contract.
Certara is holding its ground, supported by its unique relationship with regulators. The company’s 100% penetration of the top 20 pharmaceutical companies provides a stable base that competitors struggle to penetrate.
Certara’s primary protection is the high switching costs created by its regulatory integration. Because the FDA uses Certara’s software to review drug submissions, a drug company that switches to another tool takes on "regulatory risk" — the chance that the regulator will see different results or require additional data. The moat exists because switching software could literally delay the approval of a drug.
While current ROIC is low at 1.3% due to recent acquisitions and non-cash charges, gross margins of 58% and a 90% customer retention rate prove the business has real pricing power. These numbers show that once a customer adopts the software, they almost never leave. The combination of high margins and extreme retention proves that Certara provides a mission-critical tool that customers cannot easily replace.
The moat is stable, with the single most important signal being the continued use of the software by the FDA. As long as regulators use Certara as their internal standard, the company’s competitive position remains safe.
Recent 11% revenue growth is balanced by a decline in regulatory service bookings.
Recently acquired Chemaxon to expand software capabilities using existing cash.
Insider ownership is roughly 1%, which is modest for a company of this scale.
Capital Allocation Track Record
Management has done a credible job of protecting the company's cash flow during a difficult period for the biopharma industry, though strategic focus remains split. CEO Jon Resnick, who took over in 2024, is prioritizing the transition to a software-first model, which is the correct long-term move. However, the company has struggled to find a floor for its regulatory services business, which continues to act as a drag on overall growth. The recent acquisition of Chemaxon shows a disciplined approach to buying growth where it matters most: in high-margin software.
The primary governance risk is the recent transition in leadership and the lack of a large "skin in the game" ownership stake by the current executive team. While the company is well-run, it lacks the high insider ownership often found in founder-led tech companies, which means management may be less incentivized to take the bold risks needed for a major breakout. Investors should watch for whether the new CEO can successfully integrate recent acquisitions while managing the slowdown in the services unit. There is no dual-class control, and the board remains largely independent.
We expect revenue to grow from $0.4B in FY2026 to $0.6B in FY2031 (~8% CAGR), with EPS growing from $0.38 to $0.74 (~14% CAGR). Pharmaceutical companies are increasingly adopting biosimulation software to replace expensive manual clinical trials and improve drug approval success rates. High upfront software development costs are being leveraged across a growing base of recurring subscription revenue, allowing more profit to flow to the bottom line. EPS grows faster Operating margin expected to reach ~26% by FY2031.
Software segment reaches 50% of total revenue mix. As software scales, the overall business moves from 20% to 30%+ EBITDA margins, significantly increasing cash flow per share.
FDA mandates biosimulation for specific new drug classes. Any regulatory requirement for "virtual trials" would force every developer in that class to buy Certara software immediately.
AI-driven discovery partnerships drive new software license volume. Leveraging Certara's data with AI partners could open a new revenue stream in early-stage drug discovery.
Large biopharma companies cut R&D budgets for several years. A prolonged downturn in drug development spending would stall software sales and continue the decline in services.
A competitor wins a preferred software contract with the FDA. If a rival like Simulations Plus replaces Certara as the FDA standard, the primary moat would vanish overnight.
Services business enters a permanent decline that offsets software gains. If regulatory services continue to shrink faster than software grows, total company revenue and profits will stagnate.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings). This framework fits Certara because the company's value is increasingly driven by its predictable software earnings rather than its lumpy service contracts, making forward earnings the cleanest signal of its long-term compounding potential.
Applying a 30x multiple to the FY2027 EPS estimate of $0.41 yields a fair value of approximately $12 per share. Our 30x multiple sits between pure-play software peers like Simulations Plus (SLP) at 42x and diversified healthcare service providers like IQVIA at 18x; we believe Certara deserves this middle-ground positioning as its software mix surpasses 60% of revenue. We use the FY2027 EPS of $0.41 provided in the deterministic projections to reflect the first full year of operations following the recent business divestiture.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $13, which is within 8% of our $12 target and confirms our valuation stance. Using the deterministic engine's projected free cash flows and a 10% discount rate, the model accounts for the high-margin "tail" of the software business that a simple one-year multiple might miss. The close alignment between the P/E and DCF results suggests that a $12-$13 range is the most defensible intrinsic value for the stock.
We're assuming the software segment grows to represent over 60% of total revenue within two years. Following the divestiture of the low-margin regulatory writing business, Certara is shedding its "consulting firm" skin; the software business has significantly higher retention and margins, which justifies a higher consolidated multiple.
We're assuming the new ICH M15 global regulatory guidelines will act as a structural catalyst for biosimulation adoption. These guidelines establish a global framework for accepting model-informed drug development (MIDD), which effectively moves Certara's Simcyp and Phoenix platforms from "optional research tools" to "required regulatory components."
We're assuming the company maintains an adjusted EBITDA margin in the 30% to 32% range. While GAAP results show a net loss due to one-time divestiture costs and R&D, the core business remains consistently free-cash-flow positive, providing the liquidity needed to fund the transition without new debt.
The biggest risk is the ongoing shareholder litigation and CFO transition creating a permanent "uncertainty discount" on the stock's multiple. If these investigations uncover systemic accounting issues rather than just temporary execution misses, the multiple would likely stay compressed at 12x-15x, keeping the fair value near the current $5.40 price. Watch for formal class-action filings or further executive departures as early warning signs.
Bear case ($5): Software revenue growth decelerates below 8% as big pharma cuts R&D budgets; or Ongoing shareholder investigations lead to material legal settlements exceeding $50M.
Bull case ($18): Software mix reaches 65% of total revenue by FY2027, driving 500bps of margin expansion; or FDA mandates biosimulation for all Tier 1 drug approvals, making Certara's platform a "must-have".
Clearthesis wrote this report from 32 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market remains bullish because Certara provides essential simulation software that saves pharmaceutical companies from wasting hundreds of millions on failed drug trials. As drug development costs climb, the industry increasingly relies on Certara's tools to predict how treatments work in the body before testing them on real patients.
Skeptics think that multiple legal investigations into the company create too much uncertainty to justify current prices. Investors are wary of the recent wave of litigation headlines, which often signal hidden governance issues or internal struggles that could distract management from their core software growth.